The NIH National Institute of General Medical Sciences (NIGMS) awards Lectenz Bio an SBIR Phase I to develop heparan...
Lectenz Bio News
Lectenz Bio receives NIH NIGMS SBIR Phase I
The NIH National Institute of General Medical Sciences (NIGMS) awards Lectenz Bio an SBIR Phase I to develop...
Lectenz Bio at ACS Fall 2019 National Meeting
Lectenz Bio attended the ACS Fall 2019 National Meeting, where Dr. Matthew Saunders presented Glycosense™: Simple alternative to...
ASBMB Featured Story Highlights Lectenz Bio Founders
Lectenz Bio founders, Lori Yang and Rob Woods are highlighted in an ASBMB featured story, Setting Sail in a Startup: How academic...
Lectenz Bio sponsors EUROCARB XX
Christian Gerner-Smidt and Lori Yang attended the 20th European Carbohydrate Symposium in Leiden, The Netherlands. Dr. Yang gave a lecture...
Lectenz Bio completes NIH I-Corps program
Lectenz Bio completed the Spring 2019 SBIR NIH I-Corps cohort in Bethesda Maryland! During the 8-week program, our team - Sean Wu (C-Level...
Lectenz Bio presents at CYTO 2019
Dr. Lori Yang and Dr. Joshua Renfroe presented posters at the 34th Congress of the International Society for Advancement of Cytometry...
Lectenz Bio sponsors the 13th Jenner Glycobiology and Medicine Symposium
Dr. Sean Wu and Dr. Joshua Renfroe attend the 13th Jenner Glycobiology and Medicine Symposium in Cambridge, MA. Learn more about...
Lectenz Bio accepted to NIH I-Corps program
Lectenz Bio has been accepted to the National Institutes of Health (NIH) I-Corps program for SBIR phase I awardees. The goal of the...